IMRA IMARA Inc. Stock Quote

IMRA [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	22.52%	Shs Outstand	17.35M	Perf Week	-3.99%
Market Cap	210.63M	Forward P/E	-	EPS next Y	-3.84	Insider Trans	-0.16%	Shs Float	14.95M	Perf Month	-9.62%
Income	-	PEG	-	EPS next Q	-0.84	Inst Own	83.10%	Short Float	4.68%	Perf Quarter	-48.98%
Sales	-	P/S	-	EPS this Y	-107.00%	Inst Trans	13.55%	Short Ratio	5.62	Perf Half Y	-51.53%
Book/sh	5.46	P/B	2.29	EPS next Y	-0.50%	ROA	-	Target Price	-	Perf Year	-
Cash/sh	5.70	P/C	2.19	EPS next 5Y	-	ROE	-	52W Range	11.85 - 62.71	Perf YTD	-43.31%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-80.07%	Beta	-
Dividend %	-	Quick Ratio	18.80	Sales past 5Y	-	Gross Margin	-	52W Low	5.49%	ATR	0.65
Employees	16	Current Ratio	18.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	34.93	Volatility	5.99% 4.78%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-23.70%	Profit Margin	-	Rel Volume	0.46	Prev Close	12.90
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	124.68K	Price	12.50
Recom	1.30	SMA20	-8.11%	SMA50	-25.39%	SMA200	-45.64%	Volume	57,154	Change	-3.10%

Aug-17-20

Upgrade

Citigroup

Neutral → Buy

$34 → $30

Jun-30-20

Downgrade

Citigroup

Buy → Neutral

$30 → $34

Apr-06-20

Initiated

SVB Leerink

Outperform

$25

Apr-06-20

Initiated

Morgan Stanley

Overweight

$35

Apr-06-20

Initiated

Cowen

Outperform

$25

Feb-19-21 07:00AM	Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference GlobeNewswire
Jan-20-21 07:00AM	Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer GlobeNewswire
Jan-06-21 05:21PM	Imara Analyst Says Buy The Weakness Ahead Of Multiple 2021 Data Readouts Benzinga -37.97%
07:00AM	Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease GlobeNewswire
Dec-10-20 01:01AM	We Think IMARA (NASDAQ:IMRA) Can Afford To Drive Business Growth Simply Wall St. -7.63%
Dec-07-20 07:00AM	Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition GlobeNewswire
Nov-30-20 10:36PM	Do Hedge Funds Love IMARA Inc. (IMRA)? Insider Monkey -12.03%
07:00AM	Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition GlobeNewswire
Nov-17-20 07:00AM	Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory GlobeNewswire
Nov-05-20 07:00AM	Imara Reports Third Quarter 2020 Financial Results and Business Highlights GlobeNewswire
Oct-31-20 08:00AM	Kaskela Law LLC Announces Stockholder Investigation of Imara Inc. - IMRA ACCESSWIRE
Oct-29-20 07:00AM	Imara to Webcast Conference Call of Third Quarter Financial Results GlobeNewswire
Oct-16-20 07:00AM	Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia GlobeNewswire
Sep-02-20 07:00AM	Imara to Present at Upcoming Investor Conferences GlobeNewswire
Aug-25-20 07:00AM	Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease GlobeNewswire
Aug-14-20 08:26AM	The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal Benzinga
07:00AM	Imara Reports Second Quarter 2020 Financial Results and Business Highlights GlobeNewswire
Aug-13-20 04:01PM	Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease GlobeNewswire
Aug-07-20 07:00AM	Imara to Webcast Conference Call of Second Quarter 2020 Financial Results GlobeNewswire
Jul-30-20 07:00AM	Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia GlobeNewswire
Jun-29-20 04:01PM	Imara Added to Membership of U.S. Small-Cap Russell 2000® Index GlobeNewswire -16.80%
Jun-25-20 07:00AM	Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders GlobeNewswire
Jun-24-20 07:00AM	Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia GlobeNewswire -6.03%
Jun-22-20 01:57PM	Here is What Hedge Funds Think About IMARA Inc. (IMRA) Insider Monkey -5.98%
Jun-13-20 08:44AM	Here's Why We're Not Too Worried About IMARA's (NASDAQ:IMRA) Cash Burn Situation Simply Wall St.
Jun-12-20 07:46AM	Imara reports promising data from mid-stage trial for sickle cell treatment MarketWatch -16.62%
07:00AM	Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress GlobeNewswire
May-21-20 07:00AM	Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress GlobeNewswire
May-07-20 07:00AM	Imara Reports First Quarter 2020 Financial Results and Business Highlights GlobeNewswire -11.50%
May-06-20 07:00AM	Imara Launches Real Impact Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders GlobeNewswire -5.83%
May-04-20 07:00AM	Imara Announces Appointment of Stephen M. Migausky as General Counsel GlobeNewswire +5.62%
Apr-23-20 07:00AM	Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D. GlobeNewswire
Mar-11-20 09:57PM	IMARA Announces Pricing of Initial Public Offering GlobeNewswire

Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ballal Rahul D.	Chief Executive Officer	Dec 17	Option Exercise	3.15	4,999	15,747	4,999	Dec 21 04:47 PM
Ballal Rahul D.	Chief Executive Officer	Dec 17	Sale	25.00	4,999	124,975	0	Dec 21 04:47 PM
GRAY MICHAEL	CFO & COO	Dec 11	Option Exercise	4.92	1,250	6,150	1,250	Dec 15 04:26 PM
GRAY MICHAEL	CFO & COO	Dec 11	Sale	25.00	1,250	31,250	0	Dec 15 04:26 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience